Auxilium Pharmaceuticals Inc. (AUXL)

[surf1944]

7:03AM Auxilium Pharma beats by $0.08, beats on revs; lowers Xiaflex guidance (AUXL) 18.74 : Reports Q2 (Jun) loss of $0.11 per share, $0.08 better than the Capital IQ Consensus Estimate of ($0.19); revenues rose 30.5% year/year to $65.9 mln vs the $64.5 mln consensus. The co is decreasing full year 2011 guidance for XIAFLEX U.S. revenues from the previously stated guidance of a range of $50 to $60 million to a range of $45 to $50 million. -- The decrease in XIAFLEX U.S. revenues guidance changes full year 2011 net loss guidance from the previously stated guidance of a range of $(31) to $(41) million to a range of $(40) to $(45) million for the year. "We believe that the progress we made in the second quarter of 2011 will drive long term shareholder value. XIAFLEX showed double-digit sequential growth over the first quarter of 2011 and we remain encouraged by the success stories on XIAFLEX use, reflecting a steady shift in the treatment paradigm. Testim continued to perform well, despite several new competitors entering the market, with prescriptions posting growth over the second quarter of 2010 and over the first quarter 2011."